In male C57BL/6 mice, a single intraperitoneal JZL195 dose series increased brain AEA and 2-AG at 4 h while reducing endocannabinoid-hydrolyzing activities. [1]
In a mouse CCI neuropathic-pain model, JZL195 reduced mechanical and cold allodynia, with open-field suppression at higher doses. Selected anti-allodynic responses persisted through five daily injections, but the higher dose also produced behavioral effects. The 3 mg/kg regimen did not significantly improve mechanical threshold. [3]
Brain target engagement and endocannabinoid elevation
Animal study · Male C57BL/6 mice [1]
A single JZL195 dose series reduced brain FAAH/MAGL/ABHD6 activities and AEA/2-AG hydrolysis, with increased brain AEA and 2-AG relative to vehicle.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Single administration
- Treatment course
- Brain assessed 4 h later
- JZL195 dose-response series
- Model: Male C57BL/6 mice
- Reported limits: Vehicle composition not retrieved from SI.
Methods and source locations
Compound reported in the paper: JZL195
Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.
Fig. 2A–D and caption; Results, JZL195 Inhibits Endocannabinoid Hydrolysis and Elevates 2-AG and AEA Levels in Vivo
Brain hydrolase activities and endocannabinoid levels: ABPP; substrate hydrolysis; brain lipid assays. Increased AEA/2-AG and reduced hydrolysis; no exact bar heights inferred. — Fig. 2A–D and caption; corresponding Results
JZL195 dose-response series · Fig. 2A–D and caption
Acute anti-allodynic dose response and behavioral limits
Animal study · C57BL/6 mice, day 7 after sciatic-nerve chronic constriction injury (CCI) [3]
JZL195 reduced mechanical and cold allodynia. Locomotor suppression occurred at higher doses, and motor/bar assays were complicated by hyper-reactivity at the highest doses.
Conditions shared by the study groups
- Route
- Subcutaneous
- Frequency
- Single injection
- Treatment course
- Day 7 post-CCI
- Vehicle
- 2% randomly methylated β-cyclodextrin, 15% DMSO and 5% Tween-80 in saline
- Acute JZL195 dose series
- Model: C57BL/6 CCI mice; n=6/dose
Methods and source locations
Compound reported in the paper: JZL195
Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.
Methods, Drugs and administration / Experimental protocols series 3 / Analysis; Results, Effect of JZL195; Fig. 3; Table 1
Mechanical paw-withdrawal threshold: Sigmoidal dose-response fit; table reports mean (95% confidence interval); n=6/dose; figures mean ± SEM. — Table 1; Fig. 3A; Results, Effect of JZL195; Analysis
Acetone-evoked responses: Same dose-response design; mean (95% confidence interval), not SEM. — Table 1; Fig. 3A
Suppression of open-field crossings: Mean (95% confidence interval); open-field raw crossings at 2 h. — Table 1; Fig. 3C
Hyper-reactivity affecting bar/rotarod interpretation: Pop-corning prevented full sigmoidal dose responses; bar/rotarod ED50 not determined. — Results, Effect of JZL195; Table 1 footnote a; Fig. 3B
Acute JZL195 dose series · Methods, series 3; Fig. 3; Table 1
Five-day dosing preserves selected anti-allodynic responses
Animal study · C57BL/6 mice; treatment starts day 7 post-CCI [3]
Cold anti-allodynia persisted at 3 and 18 mg·kg−1 on treatment days 1 and 5. Mechanical threshold improved at 18 mg·kg−1, but not significantly at 3 mg·kg−1. Higher-dose cataleptic and locomotor effects limit interpretation.
Conditions shared by the study groups
- Route
- Subcutaneous
- Frequency
- Once daily
- Treatment course
- Five consecutive days beginning day 7 post-CCI
- Vehicle
- 2% randomly methylated β-cyclodextrin, 15% DMSO and 5% Tween-80 in saline
- JZL195 3 mg·kg−1
- Model: C57BL/6 CCI mice; n=6/group
- JZL195 18 mg·kg−1
- Model: C57BL/6 CCI mice; n=6/group
Methods and source locations
Compound reported in the paper: JZL195
Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.
Methods, series 4; Results, Repeated administration of JZL195; Fig. 6A–E and caption
Mechanical and acetone responses on treatment days 1 and 5: Pre-/post-injection comparisons; post-injection day 5 versus day 1 not significant at either dose (P>0.05); n=6/group; mean ± SEM. — Results, Repeated administration; Fig. 6A–B
Bar, rotarod and open-field responses: No significant within-day rotarod effect at either dose. Post-injection crossings did not differ significantly between days 1 and 5. — Results, Repeated administration; Fig. 6C–E
JZL195 3 mg·kg−1 · Methods, series 4; Fig. 6 and corresponding Results
JZL195 18 mg·kg−1 · Methods, series 4; Fig. 6 and corresponding Results